title: Pretreatment of crude pancreatic islets with mitomycin C prolongs graft survival time in xenogeneic rat-to-mouse model.
abstract: BACKGROUND
  Rejection of pancreatic islet grafts is still a serious problem. We evaluated the effect of mitomycin C (MMC) on the survival of crude islets grafts after xenogeneic islet transplantation.
  
  
  METHODS
  WS (RT1k) rat islets pretreated with various concentrations of MMC (0, 1, 3.2, 10, 32, 50, 100, 320, and 1,000 microg/ml) were transplanted into C57BL/6 mice with streptozotocin-induced diabetes. In vivo graft function was assessed by a daily measurement of nonfasting blood glucose concentration in each animal. We also examined the separate effect of MMC on purified islets and contaminants present in the crude islet preparation.
  
  
  RESULTS
  MMC at doses of 10, 32, 50, and 100 microg/ml resulted in a significant prolongation of the mean graft survival time from a control of 12.4+/-2.5 days to 23+/-7.4, 17.5+/-5.4, 25.5+/-14.7, and 26.7+/-8.9 days, respectively. Deterioration of glucose metabolism was noted when the dose exceeded 32 microg/ml, whereas at 320 microg/ ml, MMC failed to restore normoglycemia. Prolongation of survival time of crude islets was the result of its effect on islets and contaminant components of the crude islet preparation. In vitro study showed that MMC treatment at a higher concentration than 10 microg/ml reduces the stimulatory as well as proliferative capacity of lymph node cells.
  
  
  CONCLUSIONS
  Pretreatment of pancreatic islets with MMC at 10 microg/ml prolongs xenograft survival without deterioration of in vivo graft function. This novel treatment modality represents a new strategy for the modulation of immunity of islets and contaminants in crude islet preparations.
authors.affiliation: Department of Surgery II, Osaka University Medical School, Osaka University, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Grtochowiecki
authors.forename: M
authors.initials: M
authors.lastname: Gotoh
authors.forename: K
authors.initials: K
authors.lastname: Dono
authors.forename: Y
authors.initials: Y
authors.lastname: Takeda
authors.forename: M
authors.initials: M
authors.lastname: Nishihara
authors.forename: Y
authors.initials: Y
authors.lastname: Ohta
authors.forename: H
authors.initials: H
authors.lastname: Ota
authors.forename: H
authors.initials: H
authors.lastname: Ohzato
authors.forename: M
authors.initials: M
authors.lastname: Okuyama
authors.forename: J
authors.initials: J
authors.lastname: Shimizu
authors.forename: F
authors.initials: F
authors.lastname: Kimura
authors.forename: L
authors.initials: L
authors.lastname: He
authors.forename: H
authors.initials: H
authors.lastname: Nagano
authors.forename: S
authors.initials: S
authors.lastname: Nakamori
authors.forename: K
authors.initials: K
authors.lastname: Umeshita
authors.forename: M
authors.initials: M
authors.lastname: Sakon
authors.forename: M
authors.initials: M
authors.lastname: Monden
mesh_terms: D000818:Animals; D002455:Cell Division; D005947:Glucose / Q000378:metabolism; D006085:Graft Survival / Q000187:drug effects; D007515:Islets of Langerhans / Q000187:drug effects*; D016381:Islets of Langerhans Transplantation / Q000276:immunology; D008198:Lymph Nodes / Q000166:cytology; D008297:Male; D051379:Mice; D016685:Mitomycin / Q000494:pharmacology*; D011292:Premedication; D051381:Rats; D014183:Transplantation, Heterologous / Q000276:immunology*
chemical_list: D016685:Mitomycin; D005947:Glucose